The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population

摘要: Non-adherence to antipsychotic medication in schizophrenic patients is common and associated with symptom relapse poorer long-term outcomes. The risk factors for treatment non-adherence include dosing frequency complexity. Besides, slower dose titration an acute episode may lead attenuated efficacy. Therefore, the convenient dosage regimen rapid initiation scheme of quetiapine extended release (XR) were expected provide better effectiveness promote adherence schizophrenia. This study was implemented assess efficacy safety once-daily XR switched from other antipsychotics which suboptimal due insufficient or tolerability. a 12-week, open-label conducted Chinese population Taiwan. Patients who had score 4 (moderate) greater on any 7 items Positive Negative Syndrome Scale (PANSS) Symptom Subscale needed switch previous recruited. Quetiapine administered at 300 mg day 1, 600 mg 2 up 800 mg after 2. From 8 until end study, adjusted within 400-800 mg per day, depending clinical response tolerance patients. variable primary outcome change baseline Week 12 PANSS total subscale scores. Secondary baseline-to-endpoint difference Clinical Global Impression-Severity (CGI-S) scores participants. Sixty-one recruited 55.7% them completed study. mean changes CGI-S showed significant improvement (−18.4, p < .001 −1.0, p < .001, respectively). Four (6.7%) experienced adverse events including headache, exacerbation psychosis dysuria. use concomitant anticholinergics decreased 15.0% 8.3%. results our investigation implicated that effective well tolerated alternative treatment. Future large-scale studies are warranted validate results. ClinicalTrials.gov ID NCT02142556 . Registered 15 May 2014.